Adial Pfcf Ratio vs Net Income Per Share Analysis
| ADIL Stock | USD 1.09 0.01 0.91% |
Adial Pharmaceuticals financial indicator trend analysis is way more than just evaluating Adial Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adial Pharmaceuticals is a good investment. Please check the relationship between Adial Pharmaceuticals Pfcf Ratio and its Net Income Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
Pfcf Ratio vs Net Income Per Share
Pfcf Ratio vs Net Income Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adial Pharmaceuticals Pfcf Ratio account and Net Income Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Adial Pharmaceuticals' Pfcf Ratio and Net Income Per Share is -0.49. Overlapping area represents the amount of variation of Pfcf Ratio that can explain the historical movement of Net Income Per Share in the same time period over historical financial statements of Adial Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Adial Pharmaceuticals' Pfcf Ratio and Net Income Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pfcf Ratio of Adial Pharmaceuticals are associated (or correlated) with its Net Income Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per Share has no effect on the direction of Pfcf Ratio i.e., Adial Pharmaceuticals' Pfcf Ratio and Net Income Per Share go up and down completely randomly.
Correlation Coefficient | -0.49 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Pfcf Ratio
Net Income Per Share
Most indicators from Adial Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 0.03 this year, although the value of Selling General Administrative will most likely fall to about 5.1 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 55.1K | 648.6 | 616.17 | Interest Income | 6.5K | 106.2K | 111.6K |
Adial Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Adial Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adial Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.7M | 5.5M | 7.5M | 5.7M | 4.7M | 4.4M | |
| Total Current Liabilities | 539.1K | 1.5M | 2.7M | 1.8M | 653.1K | 1.1M | |
| Total Stockholder Equity | 7.1M | 4.0M | 3.5M | 3.3M | 4.1M | 3.1M | |
| Net Tangible Assets | 4.4M | 7.1M | 4.0M | 2.8M | 3.2M | 2.7M | |
| Net Debt | (6.8M) | (4.4M) | (5.8M) | (3.8M) | (2.8M) | (3.0M) | |
| Retained Earnings | (20.6M) | (31.5M) | (50.9M) | (63.7M) | (68.8M) | (65.4M) | |
| Accounts Payable | 190.2K | 648.7K | 286.2K | 276.4K | 127.4K | 121.0K | |
| Cash | 6.8M | 4.4M | 6.1M | 4.0M | 2.8M | 3.4M | |
| Non Current Assets Total | 6.2K | 355.6K | 1.0M | 952.9K | 1.5M | 1.6M | |
| Non Currrent Assets Other | 6.7K | 0.0 | 350K | 455K | 1.5M | 1.6M | |
| Cash And Short Term Investments | 6.8M | 4.4M | 6.1M | 4.0M | 2.8M | 3.4M | |
| Common Stock Total Equity | 3.3K | 6.9K | 10.4K | 14.4K | 13.0K | 12.3K | |
| Common Stock Shares Outstanding | 394.1K | 498.5K | 743.5K | 1.1M | 1.4M | 1.5M | |
| Liabilities And Stockholders Equity | 7.7M | 5.5M | 7.5M | 5.7M | 4.7M | 4.4M | |
| Capital Surpluse | (596.8K) | 16.5M | 27.8M | 35.5M | 40.8M | 42.9M | |
| Other Current Assets | 359.5K | 734.7K | 399.4K | 778.1K | 371.6K | 370.5K | |
| Total Liab | 539.1K | 1.5M | 4.0M | 2.5M | 653.1K | 620.4K | |
| Total Current Assets | 7.7M | 5.1M | 6.5M | 4.8M | 3.2M | 3.9M | |
| Intangible Assets | 6.2K | 5.6K | 460.0K | 459.5K | 3.9K | 3.7K | |
| Common Stock | 10.4K | 14.4K | 20.9K | 26.7K | 1.7K | 1.6K | |
| Non Current Liabilities Total | 190.2K | 648.7K | 1.2M | 665.4K | 437.0 | 415.15 | |
| Other Stockholder Equity | 27.8M | 35.5M | 54.4M | 66.9M | 72.9M | 43.0M | |
| Net Invested Capital | 7.1M | 4.0M | 3.5M | 3.3M | 3.8M | 4.0M | |
| Net Working Capital | 7.1M | 3.6M | 3.7M | 3.0M | 3.4M | 3.8M | |
| Capital Stock | 10.4K | 14.4K | 20.9K | 26.7K | 30.7K | 17.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.